Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Takeda wins temporary reprieve for controversial gout drug Colcrys

Turning the ancient gout remedy colchicine into an FDA-approved drug may not have been as costly an endeavor as developing a new med from scratch. But Takeda Pharmaceuticals still wants to reap brand-level sales for its version, dubbed Colcrys--and it's suing the FDA to make sure that happens.

Bristol-Myers, Otsuka ask judge to nix Abilify kickback suit

Did Bristol-Myers Squibb offer kickbacks and push Abilify for off-label uses? Some former sales reps-turned-whistleblowers claim it did. And given the fact that Bristol-Myers already paid $515 million to settle some off-label marketing claims related to Abilify, they say, the company violated its "we'll behave" promises to the feds.

AstraZeneca touts upbeat asthma data for key respiratory candidate

It's one step back, one step forward for AstraZeneca's key respiratory drug benralizumab.

With Allergan buy, Actavis could achieve its branded-drug ambitions

As Big Pharma's big patent cliff took hold a few years ago, generics makers enjoyed the sales boost of one newly off-patent blockbuster after another. But savvy execs knew that the unprecedented party would end soon enough--and generics companies would be facing a sort of patent cliff of their own.

Merck can't sidestep $250M gender-bias suit, judge says

The sex discrimination lawsuit against Merck lives on. A federal judge refused to toss out the $250 million suit, which claims that female sales reps were paid less, promoted less and ignored when they complained about it.

Chantix litigation may be wrapped, but safety debate wears on

Just as a federal judge says it's time to close the books on the Chantix litigation that's been moving through her Alabama court, Pfizer is preparing for another kind of fight over the drug. The company has been building its case for the FDA to clear the black-box warning off the stop-smoking drug's label, but patient groups are now petitioning the agency to add more heft to that warning instead.

Merck hops onto HBCU network to step up its brand in the African-American community

Merck's marketing team is adding another arrow to its quiver of community-oriented campaigns: a partnership with HBCU Connect, a niche media network targeting alumni and students of historically black colleges and universities.

Galderma thumbs its nose at irate U.K. marketing watchdogs

What's a drugmaker hauled up for marketing violations to do? If you're Galderma, you declare yourself exempt from the rules.

Sanofi joins list of Big Pharmas fielding bribery allegations

Now, it's Sanofi digging into potential bribery in the Middle East. The French drugmaker told U.S. officials that it's eyeing allegations from an anonymous whistleblower about improper payments from 2007 to 2012.

Sovaldi may be cost-effective, but the U.K. can't afford it, documents say

Gilead Sciences' hepatitis C drug Sovaldi may be worth the sticker price. But it's too expensive for the U.K.'s health system to bear. That's the assessment in some National Health Service documents obtained by the Health Service Journal.